File Download

There are no files associated with this item.

Conference Paper: A cost-effectiveness analysis of mammography screening in Hong Kong

TitleA cost-effectiveness analysis of mammography screening in Hong Kong
Authors
Issue Date2006
PublisherSociety for Medical Decision Making.
Citation
The 28th Annual Meeting of the Society for Medical Decision Making, Boston, MA, 15-18 October 2006. How to Cite?
AbstractPurpose: To estimate the cost-effectiveness of biennial mammography screening in a population of Hong Kong Chinese women, and to inform evidence-based interventions and public health polices in Hong Kong and East Asia with lower breast cancer incidence compared with western countries but increased concern about the cost of health care. Methods: We developed a Markov model to simulate mammography screening, breast cancer diagnosis and treatment in a hypothetical cohort of Hong Kong Chinese women. We derived model inputs from local clinical, epidemiological and economic data, and from a literature review. We modeled the benefit of mammography by assuming a stage shift (i.e., cancers in screened women were more likely to be diagnosed at an earlier stage), estimated via model calibrations with trial results. We compared life years saved (LYS) and costs for five strategies: four biennial screening strategies, beginning at age 40 or 50 and ending at age 69 or 79, and a no screening scenario. Results: Biennial mammography screening resulted in a gain in life expectancy ranging from 4.3 to 9.4 days compared with no screening at an incremental cost of US$1,170 to 2,239 per woman. The least costly non-dominated screening option was screening women from 40 to 69 years of age, with an incremental cost-effectiveness ratio (ICER) of US$64,300 per LYS compared with no screening. In probabilistic sensitivity analyses, the probability of the ICER being below a threshold of US$50,000 per LYS was 15.2%. Extending the screening program to age 79 (the next most effective strategy) would cost an additional US$238,300 per LYS. Biennial screening would be as low as US$50,000 per LYS if the age-adjusted incidence increased by a factor of 1.4. Conclusions: Our results suggest that mammography for Chinese women in Asia would likely be an inefficient use of scarce public health dollars currently. However, we must remain vigilant and periodically revisit the question of population screening as the breast cancer incidence in Hong Kong is increasing.
Persistent Identifierhttp://hdl.handle.net/10722/97886

 

DC FieldValueLanguage
dc.contributor.authorWong, OLen_HK
dc.contributor.authorKuntz, Ken_HK
dc.contributor.authorCowling, BJen_HK
dc.contributor.authorLam, CLKen_HK
dc.contributor.authorLeung, GMen_HK
dc.date.accessioned2010-09-25T17:26:21Z-
dc.date.available2010-09-25T17:26:21Z-
dc.date.issued2006en_HK
dc.identifier.citationThe 28th Annual Meeting of the Society for Medical Decision Making, Boston, MA, 15-18 October 2006.-
dc.identifier.urihttp://hdl.handle.net/10722/97886-
dc.description.abstractPurpose: To estimate the cost-effectiveness of biennial mammography screening in a population of Hong Kong Chinese women, and to inform evidence-based interventions and public health polices in Hong Kong and East Asia with lower breast cancer incidence compared with western countries but increased concern about the cost of health care. Methods: We developed a Markov model to simulate mammography screening, breast cancer diagnosis and treatment in a hypothetical cohort of Hong Kong Chinese women. We derived model inputs from local clinical, epidemiological and economic data, and from a literature review. We modeled the benefit of mammography by assuming a stage shift (i.e., cancers in screened women were more likely to be diagnosed at an earlier stage), estimated via model calibrations with trial results. We compared life years saved (LYS) and costs for five strategies: four biennial screening strategies, beginning at age 40 or 50 and ending at age 69 or 79, and a no screening scenario. Results: Biennial mammography screening resulted in a gain in life expectancy ranging from 4.3 to 9.4 days compared with no screening at an incremental cost of US$1,170 to 2,239 per woman. The least costly non-dominated screening option was screening women from 40 to 69 years of age, with an incremental cost-effectiveness ratio (ICER) of US$64,300 per LYS compared with no screening. In probabilistic sensitivity analyses, the probability of the ICER being below a threshold of US$50,000 per LYS was 15.2%. Extending the screening program to age 79 (the next most effective strategy) would cost an additional US$238,300 per LYS. Biennial screening would be as low as US$50,000 per LYS if the age-adjusted incidence increased by a factor of 1.4. Conclusions: Our results suggest that mammography for Chinese women in Asia would likely be an inefficient use of scarce public health dollars currently. However, we must remain vigilant and periodically revisit the question of population screening as the breast cancer incidence in Hong Kong is increasing.-
dc.languageengen_HK
dc.publisherSociety for Medical Decision Making.en_HK
dc.relation.ispartofAnnual Meeting of the Society for Medical Decision Makingen_HK
dc.titleA cost-effectiveness analysis of mammography screening in Hong Kongen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailCowling, BJ: bcowling@hku.hken_HK
dc.identifier.emailLam, CLK: clklam@hku.hken_HK
dc.identifier.emailLeung, GM: gmleung@hku.hken_HK
dc.identifier.authorityLam, CLK=rp00350en_HK
dc.identifier.authorityLeung, GM=rp00460en_HK
dc.identifier.hkuros125067en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats